Home・Elenco Azioni・Natera Inc

Natera Inc

Chiusa

SettoreSettore sanitario

311.83 -0.74

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

311.85

Massimo

320.62

Metriche Chiave
By Trading Economics
Entrata	18M -67M
Vendite	56M 753M
EPS	-0.47
Margine di Profitto	-8.897
Dipendenti	6,135
EBITDA	-866K -66M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+6.42% upside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	7.2B 46B
Apertura precedente	312.57
Chiusura precedente	311.83

Notizie sul Sentiment di mercato

By Acuity

23%

77%

44 / 340 Classifica in Healthcare

Natera Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 ago 2026, 20:06 UTC

News

Event

Natera Inc shares are rising after analyst upgrades and support for a Phase 1 trial in Germany using its Latitude assay to monitor tumor DNA.

11 ago 2026, 20:02 UTC

News

Natera Inc reported strong Q2 revenue of $752.8 million but shares are lower amid concerns over significant insider selling.

10 ago 2026, 20:02 UTC

News

Social Media

Natera Inc shares are lower amid negative sentiment from insider selling, despite recent analyst upgrades and price target increases from Morgan Stanley and Barclays.

7 ago 2026, 20:03 UTC

Social Media

News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6 ago 2026, 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 ago 2026, 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 ago 2026, 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 ago 2026, 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 lug 2026, 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 lug 2026, 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29 lug 2026, 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28 lug 2026, 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27 lug 2026, 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24 lug 2026, 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22 lug 2026, 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21 lug 2026, 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20 lug 2026, 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Confronto tra pari

Modifica del prezzo

Natera Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.42% in crescita

Previsioni per 12 mesi

Media 332.81 USD 6.42%

Alto 375 USD

Basso 260 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Natera Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Natera Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

44 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.